Yamada 2018 |
Japan |
UMIN000007652 |
III |
April 2012—March 2016 |
S-1 plus cisplatin plus docetaxel |
FP3 |
370 |
Adult |
NA |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
0–1 |
Gastric |
259/428 |
0.99 (95% CI, 0.85–1.16) |
0.99 (95% CI, 0.86–1.15) |
219/370 |
245/370-2 |
26/370-1 |
J Clin Oncol |
J Clin Oncol 36, 2018 (suppl; abstr 4009) |
Abstract |
S-1 plus cisplatin |
FP2 |
371 |
208/371 |
140/371-2 |
27/371-1 |
Muro 2018 |
Japan |
NCT02539225 |
II |
October 2015—October 2017 |
S-1 plus oxaliplatin plus ramucirumab |
FP2R |
96 |
Adult |
NA |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
0–1 |
Gastric and junction |
NA |
NA |
1.07 (95% CI, 0.86–1.33) |
32/55 |
NA |
NA |
J Clin Oncol |
J Clin Oncol 36, 2018 (suppl; abstr 4036) |
Abstract |
S-1 plus oxaliplatin |
FP2 |
93 |
27/54 |
Lu 2018 |
China |
NCT01015339 |
III |
December 2009—February 2014 |
Capecitabine plus paclitaxel |
FT2 |
160 |
56.6 |
115/45 |
Eastern |
151/9 |
71/89 |
8/152 |
51/109 |
Measurable |
0–2 |
92/68 |
40/40 |
0.88 (95% CI, 0.69–1.13) |
0.91 (95% CI, 0.71–1.16) |
69/160 |
100/158 |
24/158 |
Gastric Cancer |
29488121 |
|
Capecitabine plus cisplatin |
FP2 |
160 |
56.2 |
118/42 |
142/18 |
76/84 |
4/156 |
50/110 |
97/63 |
31/35 |
46/160 |
91/147 |
65/147 |
|
Fuchs 2018 |
USA |
NCT02314117 |
III |
January 2015—May 2017 |
5-FU/capecitabine plus cisplatin plus ramucirumab |
FP2R |
326 |
58.9 |
214/112 |
Versatile |
Metastatic |
NA |
NA |
NA |
Measurable |
0–2 |
Gastric and junction |
NA |
0.96 (95% CI, 0.80–1.16) |
0.75 (95% CI, 0.61–0.94) |
134/326 |
125/326-2 |
32/326-1 |
J Clin Oncol |
10.1200/JCO.2018.36.4_suppl.5 |
Abstract |
5-FU/capecitabine plus cisplatin |
FP2 |
319 |
60.1 |
215/104 |
116/319 |
131/319-2 |
5/319-1 |
Matsuyama 2018 |
Japan |
UMIN000006179 |
II |
August 2011—September 2015 |
S-1 plus docetaxel |
FT2 |
30 |
18–75 |
NA |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
Non-measurable* |
0–2 |
Gastric |
NA |
0.62 (95% CI, 0.34–1.13) |
0.70 (95% CI, 0.40–1.21) |
NA |
15/30-2 |
4/30-3 |
J Clin Oncol |
10.1200/JCO.2018.36.4_suppl.119 |
Abstract |
S-1 plus cisplatin |
FP2 |
31 |
11/31-2 |
10/31-3 |
|
Iqbal 2017 |
USA |
NCT01498289 |
II |
February 2012—March 2018 |
5-FU plus oxaliplatin plus leucovorin |
FP2 |
99 |
Adult |
NA |
Western |
Metastatic and locally unresectable |
NA |
NA |
NA |
Measurable |
0–2 |
Gastric and esophageal* |
NA |
0.82 (95% CI, 0.61–1.10) |
0.70 (95% CI, 0.52–0.93) |
33/80 |
NA |
NA |
J Clin Oncol |
10.1200/JCO.2017.35.15_suppl.4009 |
Abstract |
Docetaxel plus irinotecan |
TI2 |
104 |
23/86 |
Li 2017 |
China |
ChiCTR-TRC-08000167 |
II |
April 2008—September 2012 |
5-FU plus leucovorin plus irinotecan |
FI2 |
71 |
53 |
50/21 |
Eastern |
65/6 |
33/38 |
NA |
49/22 |
Measurable |
12/25/35 |
Gastric |
Balanced |
1.23 (95% CI, 0.87–1.75) |
1.23 (95% CI, 0.89–1.69) |
6/54 |
22/71 |
12/71 |
Oncotarget |
29228659 |
|
5-FU plus oxaliplatin plus leucovorin |
FP2 |
74 |
52 |
54/20 |
67/7 |
21/53 |
49/25 |
10/29/35 |
7/74 |
27/74 |
14/74 |
|
Hwang 2017 |
South Korea |
NCT01470742 |
III |
August 2010—October 2014 |
Capecitabine plus oxaliplatin |
FP2 |
24 |
75* |
18/6 |
Eastern |
15/9 |
NA |
NA |
11/13 |
Measurable |
20/4 |
Gastric |
NA |
0.58 (95% CI, 0.30–1.12) |
0.32 (95% CI, 0.17–0.61) |
10/24 |
4/24 |
10/24 |
J Geriatr Oncol |
28119041 |
|
Capecitabine |
F1 |
26 |
77* |
16/10 |
15/11 |
15/11 |
20/6 |
8/26 |
5/26 |
7/26 |
|
Hall 2017 |
UK |
ISCTRN33934807 |
II |
June 2009—January 2011 |
Capecitabine plus oxaliplatin plus epirubicin |
FP3 |
17 |
74* |
13/4 |
Western |
17/0 |
NA |
NA |
NA |
NA |
0/11/6 |
10/2/5*-E |
Balanced |
1 versus 2: 1.24 (95% CI, 0.39–3.94) |
1 versus 2: 0.83 (95% CI, 0.36–1.93) |
5/17 |
NA |
14/17 |
Br J Cancer |
28095397 |
|
Capecitabine plus oxaliplatin |
FP2 |
19 |
77* |
13/6 |
17/2 |
4/10/5 |
5/1/11*-E |
1 versus 3: 0.84 (95% CI, 0.41–1.73) |
1 versus 3: 0.64 (95% CI, 0.24–1.71) |
9/19 |
7/19 |
|
Capecitabine |
F1 |
19 |
75* |
15/4 |
18/1 |
2/10/7 |
7/4/8*-E |
2 versus 3: 0.38 (95% CI, 0.14–1.03) |
2 versus 3: 0.78 (95% CI, 0.34–1.79) |
2/19 |
8/19 |
|
Li 2016 |
China |
NA |
NA |
NA |
5-FU plus leucovorin plus irinotecan |
FI2 |
50 |
Adult |
NA |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
NA |
Gastric |
NA |
1.23 (95% CI, 0.81–1.88) |
0.87 (95% CI, 0.59–1.27) |
24/50 |
NA |
NA |
World Chinese Journal of Digestology |
28850174 |
Abstract |
Capecitabine plus oxaliplatin plus epirubicin |
FP3 |
55 |
22/55 |
Yoon 2016 |
USA |
NCT01246960 |
II |
April 2011—August 2012 |
5-FU plus oxaliplatin plus leucovorin plus ramucirumab |
FP2R |
84 |
64.5 |
63/21 |
Western |
80/4 |
NA |
NA |
NA |
67/17 |
40/43/0 |
19/26/39*-E |
Balanced |
1.08 (95% CI, 0.73–1.58) |
0.98 (95% CI, 0.69–1.37) |
38/84 |
27/82 |
65/82 |
Ann Oncol |
27765757 |
|
5-FU plus oxaliplatin plus leucovorin |
FP2 |
84 |
60 |
61/23 |
79/5 |
70/14 |
43/41/0 |
20/23/41*-E |
39/84 |
31/80 |
35/80 |
|
Shah 2016 |
South Korea |
NCT01590719 |
II |
July 2012—May 2013 |
5-FU plus oxaliplatin plus leucovorin plus onartuzumab |
FP2R |
62 |
58.5 |
40/22 |
Versatile |
Metastatic |
NA |
NA |
23/39 |
NA |
24/35/0 |
46/16 |
20/31 |
1.06 (95% CI, 0.64–1.75) |
1.08 (95% CI, 0.71–1.63) |
26/43 |
41/60-2 |
10/60-2 |
Oncologist |
27401892 |
|
5-FU plus oxaliplatin plus leucovorin |
FP2 |
61 |
57 |
36/25 |
20/41 |
24/36/0 |
48/13 |
23/26 |
24/42 |
29/60-2 |
1/60-2 |
|
Tebbutt 2016 |
Australia |
ACTRN12609000109202 |
II |
April 2010—November 2011 |
5-FU/capecitabine plus cisplatin plus docetaxel plus panitumumab |
FP3R |
37 |
64 |
33/4 |
Western |
Metastatic and locally unresectable |
26/11 |
13/24 |
NA |
Measurable |
34/3 |
13/10/15*-E |
Balanced |
1.02 (95% CI, 0.51–2.05) |
1.08 (95% CI, 0.59–2.01) |
22/37 |
NA |
26/37 |
Br J Cancer |
26867157 |
|
5-FU/capecitabine plus cisplatin plus docetaxel |
FP3 |
39 |
59 |
30/9 |
23/16 |
5/34 |
37/2 |
15/11/13*-E |
17/39 |
18/39 |
|
Hironaka 2016 |
Japan |
JapicCTI-111635 |
II |
October 2011—December 2012 |
S-1 plus oxaliplatin plus leucovorin |
FP2 |
47 |
65 |
33/14 |
Eastern |
40/7 |
NA |
12/35 |
NA |
Measurable |
37/10/0 |
Gastric |
24/23 |
1 versus 2: 0.76 (95% CI, 0.47–1.24) |
1 versus 2: 0.52 (95% CI, 0.30–0.88) |
31/47 |
25/47 |
28/47-3 |
Lancet Oncol |
26640036 |
|
S-1 plus leucovorin |
F1 |
47 |
65 |
37/10 |
40/7 |
11/36 |
37/10/0 |
24/23 |
1 versus 3: 0.59 (95% CI, 0.37–0.93) |
1 versus 3: 0.60 (95% CI, 0.35–1.02) |
20/47 |
11/47 |
10/47-3 |
|
S-1 plus cisplatin |
FP2 |
48 |
65 |
38/10 |
41/7 |
14/34 |
38/10/0 |
18/30 |
2 versus 3: 0.77 (95% CI, 0.49–1.22) |
2 versus 3: 1.08 (95% CI, 0.67–1.74) |
22/48 |
43/48 |
22/48-3 |
|
Wang 2016 |
China |
NCT00811447 |
III |
November 2008—June 2012 |
5-FU plus cisplatin plus docetaxel |
FP3 |
119 |
56.6 |
81/38 |
Eastern |
89/30 |
NA |
NA |
46/73 |
Measurable |
115/4 |
99/20 |
Balanced |
0.71 (95% CI, 0.52–0.97) |
0.58 (95% CI, 0.42–0.80) |
58/119 |
72/119-1 |
31/119 |
Gastric Cancer |
25604851 |
|
5-FU plus cisplatin |
FP2 |
115 |
55.5 |
88/27 |
89/26 |
39/76 |
108/7 |
86/29 |
39/115 |
11/115-1 |
21/115 |
|
Du 2015 |
China |
NCT02370849 |
II |
October 2009—February 2012 |
S-1 plus cisplatin plus nimotuzumab |
FP2R |
31 |
58 |
17/14 |
Eastern |
22/9 |
6/25 |
4/27 |
8/23 |
Measurable |
5/26/0 |
25/6 |
Balanced |
1.78 (95% CI, 0.97–3.25) |
2.14 (95% CI, 1.19–3.83) |
17/31 |
8/31 |
6/31 |
Medicine |
26061330 |
|
S-1 plus cisplatin |
FP2 |
31 |
53 |
26/5 |
18/13 |
3/28 |
5/26 |
9/22 |
7/24/0 |
25/6 |
18/31 |
4/31 |
1/31 |
|
Wu 2015 |
China |
ChiCTR-TRC-13003993* |
NA |
July 2009—June 2011 |
S-1 plus cisplatin |
FP2 |
36 |
64.1 |
25/11 |
Eastern |
31/5 |
NA |
NA |
16/20 |
Measurable |
15/21/0 |
Gastric |
21/13 |
0.81 (95% CI, 0.46–1.43) |
0.76 (95% CI, 0.40–1.46) |
19/36 |
25/36 |
30/36 |
Anticancer Drugs |
25933246 |
|
Cisplatin |
P1 |
36 |
62.7 |
23/23 |
30/6 |
18/18 |
16/20/0 |
22/11 |
15/36 |
19/36 |
24/36 |
|
Van Cutsem 2015 |
Belgium |
NCT00382720 |
II |
September 2006—September 2007 |
5-FU plus oxaliplatin plus leucovorin plus docetaxel |
FP3 |
89 |
58 |
61/28 |
Western |
Metastatic and locally unresectable |
63/26 |
17/72 |
35/54 |
77/12 |
87/2 |
75/14 |
NA |
1 versus 2: 0.73 (95% CI, 0.48–1.09) |
1 versus 2: 0.80 (95% CI, 0.55–1.18) |
41/88 |
49/88-1 |
67/88 |
Ann Oncol |
25416687 |
|
Capecitabine plus oxaliplatin plus docetaxel |
FP3 |
86 |
59 |
64/22 |
50/36 |
17/69 |
40/46 |
80/6 |
84/2 |
75/11 |
1 versus 3: 0.51 (95% CI, 0.35–0.76) |
1 versus 3: 0.43 (95% CI, 0.30–0.63) |
21/81 |
50/82-1 |
73/82 |
|
Oxaliplatin plus docetaxel |
PT2 |
79 |
59 |
51/28 |
55/24 |
7/72 |
23/56 |
69/10 |
77/2 |
70/9 |
2 versus 3: 0.75 (95% CI, 0.51–1.10) |
2 versus 3: 0.69 (95% CI, 0.49–0.96) |
18/78 |
52/78-1 |
76/78 |
|
Shen 2015 |
China |
NCT00887822 |
III |
March 2009—July 2010 |
Capecitabine plus cisplatin plus bevacizumab |
FP2R |
100 |
54.2 |
68/32 |
Eastern |
95/5 |
39/61 |
NA |
24/76 |
81/19 |
95/5 |
85/15 |
Balanced |
1.11 (95% CI, 0.79–1.56) |
0.89 (95% CI, 0.66–1.21) |
33/81 |
54/100 |
66/100 |
Gastric Cancer |
24557418 |
|
Capecitabine plus cisplatin |
FP2 |
102 |
55.5 |
74/28 |
94/8 |
40/62 |
20/82 |
86/16 |
97/5 |
82/20 |
29/86 |
68/101 |
45/101 |
|
Guimbaud 2014 |
France |
NCT00374036 |
III |
June 2005—May 2008 |
5-FU plus leucovorin plus irinotecan |
FI2 |
207 |
61.4 |
155/52 |
Western |
176/31 |
NA |
NA |
48/159 |
Measurable |
71/102/27 |
138/63 |
Balanced |
1.01 (95% CI, 0.82–1.24) |
0.99 (95% CI, 0.81–1.21) |
75/198 |
78/203 |
108/203 |
J Clin Oncol |
25287828 |
|
Capecitabine plus cisplatin plus epirubicin |
FP3 |
209 |
61.4 |
154/55 |
173/36 |
54/155 |
61/108/36 |
133/73 |
74/189 |
129/200 |
107/200 |
|
Iveson 2014 |
UK |
NCT00719550 |
II |
October 2009—June 2010 |
Capecitabine plus cisplatin plus epirubicin plus rilotumumab |
FP3R |
82 |
61 |
57/25 |
Western |
73/9 |
NA |
NA |
13/69 |
76/6 |
34/47/1 |
66/12 |
NA |
0.70 (95% CI, 0.45–1.09) |
0.60 (95% CI, 0.45–0.79) |
30/76 |
56/81 |
68/81 |
Lancet Oncol |
24965569 |
|
Capecitabine plus cisplatin plus epirubicin |
FP3 |
39 |
60 |
31/8 |
34/5 |
9/30 |
38/1 |
16/22/1 |
31/4 |
8/38 |
16/39 |
32/39 |
|
Zhang 2014 |
China |
NA |
NA |
August 2010—September 2012 |
S-1 plus oxaliplatin plus cetuximab |
FP2R |
30 |
49 |
37/19 |
Eastern |
Metastatic and locally unresectable |
26/30 |
8/48 |
12/44 |
Measurable |
3/47/6 |
Gastric |
25/31 |
0.74 (95% CI, 0.42–1.30) |
0.67 (95% CI, 0.38–1.18) |
17/30 |
10/30 |
3/30 |
World J Surg Oncol |
24758484 |
|
S-1 plus oxaliplatin |
FP2 |
26 |
11/26 |
11/26 |
5/26 |
|
Lu 2014 |
China |
NA |
II |
January 2009—December 2011 |
S-1 plus oxaliplatin |
FP2 |
47 |
63 |
34/13 |
Eastern |
Metastatic and locally unresectable |
18/29 |
19/28 |
NA |
Measurable |
34/8/5 |
Gastric |
12/32 |
0.60 (95% CI, 0.39–0.94) |
0.57 (95% CI, 0.36–0.91) |
24/47 |
39/47 |
27/47 |
J Chemother |
24621155 |
|
S-1 |
F1 |
47 |
65 |
33/14 |
16/31 |
20/27 |
33/10/4 |
10/33 |
13/47 |
15/47 |
15/47 |
|
Sugimoto 2014 |
Japan |
UMIN000000638 |
II |
December 2004—November 2007 |
S-1 plus paclitaxel |
FT2 |
51 |
62 |
38/13 |
Eastern |
40/11 |
NA |
NA |
14/37 |
Measurable |
39/12/0 |
Gastric |
33/16 |
0.99 (95% CI, 0.64–1.52) |
1.18 (95% CI, 0.79–1.79) |
16/51 |
3/51 |
14/51 |
Anticancer Res |
24511022 |
|
S-1 plus irinotecan |
FI2 |
51 |
64 |
38/13 |
40/11 |
14/37 |
41/8/2 |
28/22 |
17/51 |
22/48 |
15/48 |
|
Koizumi 2014 |
Japan |
NCT00287768 |
III |
September 2005—September 2008 |
S-1 plus docetaxel |
FT2 |
314 |
65 |
227/87 |
Eastern |
260/54 |
127/187 |
119/195 |
168/146 |
242/72 |
137/177/0 |
Gastric and junction |
NA |
0.84 (95% CI, 0.71–0.99) |
0.77 (95% CI, 0.65–0.90) |
92/237 |
208/310 |
130/310 |
J Cancer Res Clin Oncol |
24366758 |
|
S-1 |
F1 |
321 |
65 |
229/92 |
267/54 |
135/186 |
131/190 |
163/158 |
249/72 |
147/174/0 |
65/243 |
49/313 |
129/313 |
|
Koizumi 2013 |
Japan |
JapicCTI-101327 |
II |
December 2008—February 2012 |
S-1 plus cisplatin plus orantinib |
FP2R |
45 |
62 |
30/15 |
Eastern |
39/6 |
19/26 |
15/30 |
NA |
Measurable |
28/17/0 |
Gastric |
22/23 |
0.74 (95% CI, 0.46-1.19) |
1.23 (95% CI, 0.74–2.05) |
28/45 |
36/45-2 |
27/45 |
Br J Cancer |
24045669 |
|
S-1 plus cisplatin |
FP2 |
46 |
63.5 |
35/11 |
39/7 |
24/22 |
15/31 |
30/16/0 |
25/20 |
26/46 |
28/46-2 |
14/46 |
|
Shirao 2013 |
Japan |
NCT00149201 |
III |
October 2002—April 2007 |
5-FU plus leucovorin plus methotrexate |
FM2 |
118 |
59 |
70/48 |
Eastern |
Metastatic |
NA |
118/0* |
96/22 |
NA |
46/68/4 |
Gastric |
26/92 |
0.94 (95% CI, 0.72–1.22) |
NA |
NA |
81/116 |
110/116 |
Jpn J Clin Oncol |
24014884 |
|
5-FU |
F1 |
119 |
61 |
66/53 |
119/0* |
91/28 |
46/69/4 |
25/94 |
13/117 |
77/117 |
|
Richards 2013 |
USA |
NCT00517829 |
II |
December 2007—April 2010 |
Oxaliplatin plus docetaxel |
PT2 |
75 |
61.7 |
59/16 |
Western |
62/13 |
65/10 |
NA |
NA |
Measurable |
26/42/7 |
37/38 |
Balanced |
0.94 (95% CI, 0.65–1.36) |
1.00 (95% CI, 0.67–1.49) |
18/68 |
53/68 |
25/68 |
Eur J Cancer |
23747051 |
|
Oxaliplatin plus docetaxel plus cetuximab |
PT2R |
75 |
64 |
60/15 |
55/20 |
63/12 |
33/33/9 |
34/41 |
27/71 |
58/72 |
46/72 |
|
Waddell 2013 |
UK |
NCT00824785 |
III |
June 2008—October 2011 |
Capecitabine plus oxaliplatin plus epirubicin plus panitumumab |
FP3R |
278 |
63 |
232/46 |
Western |
244/34 |
NA |
NA |
NA |
Measurable |
118/144/16 |
78/94/106*-E |
Balanced |
1.37 (95% CI, 1.07–1.76) |
1.22 (95% CI, 0.98–1.52) |
116/254 |
69/276 |
264/276 |
Lancet Oncol |
23594787 |
|
Capecitabine plus oxaliplatin plus epirubicin |
FP3 |
275 |
62 |
226/49 |
250/25 |
117/143/15 |
89/75/111*-E |
100/238 |
137/266 |
190/266 |
|
Lordick 2013 |
Germany |
EudraCT2007-004219-75 |
III |
June 2008—December 2010 |
Capecitabine plus cisplatin plus cetuximab |
FP2R |
455 |
60 |
339/116 |
Versatile |
439/16 |
NA |
113/342 |
92/363 |
Measurable |
237/218/0 |
376/71 |
162/76 |
1.00 (95% CI, 0.87–1.17) |
1.09 (95% CI, 0.92–1.29) |
136/455 |
178/446 |
430/446 |
Lancet Oncol |
23594786 |
|
Capecitabine plus cisplatin |
FP2 |
449 |
59 |
334/115 |
436/12 |
116/333 |
90/359 |
228/220/0 |
371/73 |
149/94 |
131/449 |
234/436 |
278/436 |
|
Wang 2013 |
China |
NA |
II |
January 2008—September 2010 |
S-1 plus paclitaxel |
FT2 |
41 |
63 |
32/9 |
Eastern |
Metastatic and locally unresectable |
16/25 |
15/26 |
15/26 |
Measurable |
31/6/4 |
Gastric |
11/28 |
0.55 (95% CI, 0.34–0.90) |
0.60 (95% CI, 0.37–0.97) |
19/41 |
32/41 |
36/41 |
Clin Transl Oncol |
23381898 |
|
S-1 |
F1 |
41 |
61 |
30/11 |
14/27 |
17/24 |
17/24 |
29/9/3 |
10/30 |
10/41 |
13/41 |
14/41 |
|
Eatock 2013 |
UK |
NCT00583674 |
II |
December 2007—July 2009 |
Capecitabine plus cisplatin plus trebananib |
FP2R |
115 |
59 |
85/30 |
Western |
Metastatic |
NA |
NA |
7/108 |
100/15 |
54/60/1 |
76/21/18*-E |
NA |
Median OS time |
0.98 (95% CI, 0.67–1.43) |
35/100 |
33/114 |
44/114-3 |
Ann Oncol |
23108953 |
|
Capecitabine plus cisplatin |
FP2 |
56 |
62 |
45/11 |
5/51 |
49/7 |
29/25/2 |
33/11/12*-E |
17/49 |
24/53 |
22/49-3 |
|
Al-Batran 2013 |
Germany |
NCT00737373 |
II |
August 2007—October 2008 |
5-FU plus oxaliplatin plus leucovorin plus docetaxel |
FP3 |
72 |
69* |
51/21 |
Western |
50/22 |
33/39 |
14/58 |
18/54 |
Measurable |
67/5 |
45/27 |
NA |
0.83 (95% CI, 0.54–1.28) |
0.80 (95% CI, 0.54–1.20) |
35/72 |
59/72-2 |
58/72 |
Eur J Cancer |
23063354 |
|
5-FU plus oxaliplatin plus leucovorin |
FP2 |
71 |
70* |
45/26 |
49/22 |
32/39 |
14/57 |
18/53 |
65/6 |
47/24 |
20/71 |
16/70-2 |
46/70 |
|
Andrić 2012 |
Serbia |
NA |
NA |
2006–2009 |
5-FU plus doxorubicin plus mitomycin-C |
FA3 |
25 |
61 |
18/7 |
Western |
21/4 |
NA |
NA |
9/16 |
NA |
3/22/0 |
Gastric |
7/18 |
1.17 (95% CI, 0.55–2.47) |
NA |
5/25 |
3/25 |
22/25 |
Srp Arh Celok Lek |
22826983 |
Serbian |
5-FU plus cisplatin plus leucovorin |
FP2 |
25 |
57 |
20/5 |
20/5 |
10/15 |
6/19/0 |
6/19 |
6/25 |
0/25 |
7/25 |
|
Roy 2012 |
UK |
NA |
II |
August 1999—August 2000 |
Docetaxel plus irinotecan |
TI2 |
42 |
62 |
35/7 |
Western |
40/2 |
NA |
NA |
16/26 |
Measurable |
7/29/6 |
27/15 |
Balanced |
0.79 (95% CI, 0.52–1.22) |
Median PFS time |
13/42 |
35/42-1 |
35/42-3 |
Br J Cancer |
22767144 |
|
5-FU plus docetaxel |
FT2 |
43 |
60 |
35/8 |
40/3 |
15/28 |
9/22/12 |
19/24 |
11/43 |
30/43-1 |
18/43-3 |
|
Mochiki 2012 |
Japan |
NA |
II |
January 2006—November 2010 |
S-1 plus paclitaxel |
FT2 |
42 |
63.3 |
31/11 |
Eastern |
Metastatic and locally unresectable |
14/28 |
11/31 |
9/33 |
Measurable |
38/4/0 |
Gastric |
16/26 |
0.94 (95% CI, 0.55–1.63) |
0.84 (95% CI, 0.50–1.40) |
22/42 |
8/42 |
6/42 |
Br J Cancer |
22617130 |
|
S-1 plus cisplatin |
FP2 |
41 |
63 |
30/11 |
12/29 |
8/33 |
8/33 |
39/2/0 |
16/25 |
20/41 |
8/41 |
7/41 |
|
Ohtsu 2011 |
Japan |
NCT00548548 |
III |
September 2007—December 2008 |
Capecitabine plus cisplatin plus bevacizumab |
FP2R |
387 |
58 |
257/130 |
Versatile |
367/20 |
130/257 |
NA |
110/277 |
311/76 |
365/22 |
333/54 |
NA |
0.87 (95% CI, 0.73–1.04) |
0.80 (95% CI, 0.68–0.93) |
143/311 |
194/386 |
165/386 |
J Clin Oncol |
21844504 |
|
Capecitabine plus cisplatin |
FP2 |
387 |
59 |
258/129 |
378/9 |
126/261 |
107/280 |
297/90 |
367/20 |
338/49 |
111/297 |
209/381 |
183/381 |
|
Jeung 2011 |
South Korea |
NA |
II |
July 2005—April 2007 |
S-1 plus docetaxel |
FT2 |
39 |
56 |
31/8 |
Eastern |
29/10 |
10/29 |
14/25 |
12/27 |
Measurable |
35/4 |
Gastric |
Balanced |
0.56 (95% CI, 0.35–0.88) |
0.63 (95% CI, 0.38–1.05) |
18/39 |
Description |
24/39 |
Cancer |
21523716 |
|
Cisplatin plus docetaxel |
PT2 |
41 |
60 |
28/13 |
34/7 |
10/31 |
12/29 |
9/32 |
35/6 |
10/41 |
16/41 |
|
Komatsu 2011 |
Japan |
NA |
II |
August 2003—March 2005 |
S-1 plus irinotecan |
FI2 |
48 |
70* |
34/14 |
Eastern |
33/15 |
NA |
NA |
2/46 |
Measurable |
38/10/0 |
Gastric |
Balanced |
0.95 (95% CI, 0.64–1.41) |
0.78 (95% CI, 0.54–1.13) |
12/48 |
21/48 |
30/48 |
Anticancer Drugs |
21512394 |
|
S-1 |
F1 |
47 |
63* |
37/10 |
33/14 |
4/43 |
35/12/0 |
7/47 |
12/47 |
16/47 |
|
Li 2011 |
China |
NA |
II |
January 2003—December 2007 |
5–FU plus cisplatin plus paclitaxel |
FP3 |
50 |
59 |
32/18 |
Eastern |
28/22 |
NA |
NA |
NA |
Measurable |
24/26 |
Gastric |
Balanced |
1.02 (95% CI, 0.63–1.66) |
NA |
24/50 |
4/50-1 |
5/50-1 |
World J Gastroenterol |
21448363 |
|
5-FU plus oxaliplatin plus leucovorin |
FP2 |
44 |
58 |
31/13 |
27/17 |
21/23 |
20/44 |
4/44-1 |
0/44-1 |
|
Narahara 2011 |
Japan |
JapicCTI-050083 |
III |
June 2004—November 2005 |
S-1 plus irinotecan |
FI2 |
155 |
63 |
110/45 |
Eastern |
129/26 |
110/205 |
105/210 |
93/62 |
Measurable |
102/48/5 |
Gastric |
61/93 |
0.89 (95% CI, 0.70–1.15) |
0.86 (95% CI, 0.68–1.08) |
39/94 |
89/155 |
98/155 |
Gastric Cancer |
21340666 |
|
S-1 |
F1 |
160 |
63 |
127/33 |
133/27 |
93/67 |
109/46/5 |
71/88 |
25/93 |
53/160 |
87/160 |
|
Tebbutt 2010 |
Australia |
NA |
II |
June 2004—May 2006 |
5-FU plus cisplatin plus docetaxel |
FP3 |
50 |
60.5 |
42/8 |
Western |
48/2 |
32/18 |
10/40 |
NA |
Measurable |
21/28/1 |
26/13/11*-E |
Balanced |
0.84 (95% CI, 0.50–1.39) |
0.73 (95% CI, 0.48–1.13) |
22/47 |
8/49 |
38/49-4 |
Br J Cancer |
20068567 |
|
Capecitabine plus docetaxel |
FT2 |
56 |
59.1 |
42/14 |
51/5 |
43/13 |
6/50 |
31/23/2 |
23/13/20*-E |
14/53 |
2/55 |
23/55-4 |
|
Yun 2010 |
South Korea |
NCT00743964 |
II |
April 2008—October 2009 |
Capecitabine plus cisplatin plus epirubicin |
FP3 |
44 |
55 |
28/16 |
Eastern |
Metastatic and locally unresectable |
12/32 |
26/18 |
17/27 |
Measurable |
40/1 |
Gastric |
NA |
NA |
0.96 (95% CI, 0.58–1.57) |
16/43 |
31/44 |
40/44 |
Eur J Cancer |
20060288 |
|
Capecitabine plus cisplatin |
FP2 |
45 |
58 |
34/11 |
19/26 |
23/22 |
20/25 |
41/4 |
17/45 |
22/45 |
32/45 |
|
Moehler 2010 |
Germany |
NA |
II |
October 2003—December 2006 |
Capecitabine plus irinotecan |
FI2 |
57 |
61 |
42/15 |
Western |
Metastatic |
44/13 |
18/39 |
20/37 |
NA |
0–2 |
49/7 |
NA |
0.77 (95% CI, 0.51–1.17) |
1.14 (95% CI, 0.59–2.21) |
20/53 |
33/57 |
50/57 |
Ann Oncol |
19605504 |
|
Capecitabine plus cisplatin |
FP2 |
55 |
64 |
36/19 |
38/17 |
20/35 |
14/41 |
38/17 |
21/50 |
48/55 |
54/55 |
|
Ikeda 2009 |
Japan |
NA |
II |
June 2005—August 2008 |
S-1 plus docetaxel |
FT2 |
24 |
58 |
19/5 |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
21/3 |
Gastric |
NA |
0.53 (95% CI, 0.28–0.99) |
0.53 (95% CI, 0.28–0.97) |
21/24 |
22/24-2 |
3/24-3 |
J Clin Oncol |
10.1200/jco.2009.27.15s.4595 |
Abstract |
5-FU plus cisplatin |
FP2 |
25 |
65 |
23/2 |
23/2 |
13/25 |
8/25-2 |
18/25-3 |
Boku 2009 |
Japan |
NCT00142350 |
III |
November 2000—January 2006 |
Cisplatin plus irinotecan |
PI2 |
236 |
63 |
180/56 |
Eastern |
190/46 |
NA |
76/160 |
NA |
NA |
151/81/4 |
Gastric |
102/134 |
1 versus (2+3): 0.82 (95% CI, 0.68–0.99) |
1 versus (2+3): 0.73 (95% CI, 0.64–0.83) |
68/181 |
152/234-1 |
172/234 |
Lancet Oncol |
19818685 |
|
S-1 |
F1 |
234 |
64 |
175/59 |
188/46 |
69/165 |
151/80/3 |
110/124 |
49/174 |
30/234-1 |
94/234 |
|
5-FU |
F1 |
234 |
63.5 |
176/58 |
189/45 |
87/147 |
152/79/3 |
111/121 |
15/175 |
36/232-1 |
57/232 |
|
Ridwelski 2008 |
Germany |
NA |
III |
NA |
Cisplatin plus docetaxel |
PT2 |
137 |
62 |
NA |
Western |
243/27 |
NA |
NA |
NA |
NA |
0–2 |
Gastric |
NA |
1.06 (95% CI, 0.82–1.37) |
1.10 (95% CI, 0.85–1.42) |
32/117 |
56/137-1 |
27/137-1 |
J Clin Oncol |
10.1200/jco.2008.26.15_suppl.4512 |
Abstract |
5-FU plus cisplatin plus leucovorin |
FP2 |
133 |
33/117 |
16/133-1 |
38/133-1 |
Tesselaar 2008 |
Netherlands |
NA |
II |
NA |
5-FU plus leucovorin plus paclitaxel |
FT2 |
47 |
NA |
NA |
Western |
Metastatic |
NA |
NA |
NA |
Measurable |
NA |
Gastric and junction |
NA |
0.79 (95% CI, 0.52–1.20) |
Median PFS time |
21/47 |
Description |
13/47 |
J Clin Oncol |
10.1200/jco.2008.26.15_suppl.4567 |
Abstract |
5-FU plus cisplatin plus leucovorin |
FP2 |
49 |
23/49 |
17/49 |
Jin 2008 |
China |
NCT00202969 |
III |
July 2005—October 2006 |
S-1 |
F1 |
77 |
57 |
56/21 |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
65/12 |
Gastric |
NA |
(2+3) versus 1: 0.55 (95% CI, 0.36–0.83) |
Median PFS time |
19/77 |
6/77 |
4/77 |
J Clin Oncol |
10.1200/jco.2008.26.15_suppl.4533 |
Abstract |
S-1 plus cisplatin |
FP2 |
74 |
56.5 |
55/19 |
66/8 |
28/74 |
26/74 |
17/74 |
5-FU plus cisplatin |
FP2 |
73 |
58 |
61/12 |
63/10 |
14/73 |
23/73 |
22/73 |
Dank 2008 |
Hungary |
NA |
III |
June 2000—March 2002 |
5-FU plus cisplatin |
FP2 |
163 |
59 |
108/55 |
Western |
155/8 |
91/72 |
41/122 |
66/97 |
Measurable |
27/134/2 |
132/31 |
42/46 |
1.08 (95% CI, 0.86–1.35) |
1.23 (95% CI, 0.97–1.57) |
42/163 |
155/166-3 |
128/166 |
Ann Oncol |
18558665 |
|
5-FU plus leucovorin plus irinotecan |
FI2 |
170 |
58 |
125/45 |
163/7 |
101/69 |
40/130 |
70/100 |
45/124/1 |
136/34 |
49/60 |
54/170 |
88/167-3 |
119/167 |
|
Koizumi 2008 |
Japan |
NCT00150670 |
III |
March 2002—November 2004 |
S-1 plus cisplatin |
FP2 |
148 |
62 |
108/40 |
Eastern |
118/30 |
60/88 |
51/97 |
53/95 |
NA |
106/38/4 |
Gastric |
45/103 |
0.77 (95% CI, 0.61–0.98) |
0.57 (95% CI, 0.44–0.73) |
47/87 |
127/148 |
88/148 |
Lancet Oncol |
18282805 |
|
S-1 |
F1 |
150 |
62 |
116/34 |
119/31 |
60/90 |
36/114 |
58/92 |
106/39/5 |
60/89 |
33/106 |
27/150 |
24/150 |
|
Park 2008 |
South Korea |
NCT00320294 |
II |
October 2004—November 2006 |
5-FU plus cisplatin plus leucovorin plus irinotecan |
FP3 |
45 |
51 |
30/15 |
Eastern |
Metastatic and locally unresectable |
16/29 |
26/19 |
29/16 |
Measurable |
38/7 |
Gastric |
NA |
0.84 (95% CI, 0.38–1.89) |
0.72 (95% CI, 0.44–1.19) |
19/45 |
27/45 |
29/45 |
Ann Oncol |
18083691 |
|
5-FU plus leucovorin plus irinotecan |
FI2 |
46 |
55 |
30/16 |
21/25 |
30/16 |
43/3 |
35/11 |
19/46 |
17/45 |
36/45 |
|
Popov 2008 |
Serbia |
NA |
II |
August 1998—September 2001 |
Cisplatin plus doxorubicin plus etoposide |
PA3 |
30 |
57 |
21/9 |
Western |
27/3 |
18/12 |
10/20 |
24/6 |
Measurable |
3/22/5 |
21/9 |
Balanced |
0.86 (95% CI, 0.32–2.29) |
Median PFS time |
10/30 |
Cycles |
Cycles |
Med Oncol |
17972024 |
|
5-FU |
F1 |
30 |
55 |
23/7 |
22/8 |
17/13 |
11/19 |
22/8 |
6/19/5 |
19/11 |
3/30 |
|
Roth 2007 |
Switzerland |
NA |
II |
September 1999—July 2003 |
5-FU plus cisplatin plus docetaxel |
FP3 |
41 |
61 |
30/11 |
Western |
39/2 |
17/24 |
9/32 |
13/28 |
Measurable |
25/16 |
Gastric |
NA |
(1+2) versus 3: 0.96 (95% CI, 0.59–1.54) |
(1+2) versus 3: 0.79 (95% CI, 0.49–1.27) |
15/41 |
33/41-1 |
37/41 |
J Clin Oncol |
17664469 |
|
5-FU plus cisplatin plus epirubicin |
FP3 |
40 |
59 |
30/10 |
33/7 |
16/24 |
5/35 |
7/33 |
24/16 |
10/40 |
24/40-1 |
23/40 |
|
Cisplatin plus docetaxel |
PT2 |
38 |
58 |
29/9 |
31/7 |
15/23 |
3/34 |
9/29 |
23/15 |
7/38 |
29/38-1 |
32/38 |
|
Lutz 2007 |
Germany |
NA |
II |
January 1996—August 1999 |
5-FU plus cisplatin plus leucovorin |
FP2 |
51 |
62 |
40/11 |
Western |
45/6 |
NA |
NA |
23/28 |
50/1 |
49/2 |
Gastric |
22/13 |
1 versus 2: 0.66 (95% CI, 0.42–1.06) |
Median PFS time |
21/46 |
20/51 |
32/51 |
J Clin Oncol |
17577037 |
|
5-FU plus leucovorin |
F1 |
53 |
53 |
42/11 |
47/6 |
26/27 |
53/0 |
49/4 |
27/10 |
1 versus 3: 0.57 (95% CI, 0.35–0.94) |
12/48 |
4/53 |
12/48 |
|
5-FU |
F1 |
37 |
37 |
30/7 |
29/8 |
22/15 |
36/1 |
34/3 |
20/6 |
2 versus 3: 0.83 (95% CI, 0.50–1.37) |
2/33 |
5/37 |
12/33 |
|
Van Cutsem 2006 |
Belgium |
NA |
III |
November 1999—January 2003 |
5-FU plus cisplatin |
FP2 |
224 |
55 |
158/66 |
Western |
217/6 |
NA |
NA |
71/153 |
Measurable |
29/192/3 |
168/56 |
45/77 |
1.29 (95% CI, 1.02–1.63) |
1.47 (95% CI, 1.19–1.82) |
57/224 |
126/224-1 |
206/224-3 |
J Clin Oncol |
17075117 |
|
5-FU plus cisplatin plus docetaxel |
FP3 |
221 |
55 |
159/62 |
213/6 |
68/153 |
28/190/3 |
179/42 |
40/92 |
81/221 |
181/221-1 |
197/221-3 |
|
Ajani 2005 |
USA |
NA |
II |
June 1998—September 1999 |
5-FU plus cisplatin plus docetaxel |
FP3 |
79 |
57 |
61/18 |
Western |
75/4 |
NA |
NA |
28/51 |
Measurable |
7/72/0 |
50/29 |
16/30 |
1.19 (95% CI, 0.83–1.69) |
0.80 (95% CI, 0.52–1.22) |
34/79 |
66/79-1 |
73/79-4 |
J Clin Oncol |
16110025 |
|
Cisplatin plus docetaxel |
PT2 |
76 |
57 |
53/23 |
72/4 |
30/46 |
10/65/1 |
56/20 |
20/17 |
20/76 |
65/76-1 |
39//76-4 |
|
Moehler 2005 |
Germany |
NA |
II |
November 2000—April 2003 |
5-FU plus leucovorin plus etoposide |
FE2 |
58 |
63 |
49/9 |
Western |
Metastatic and locally unresectable |
42/16 |
11/47 |
31/27 |
Measurable |
8/43/7 |
42/16 |
NA |
1.25 (95% CI, 0.83–1.86) |
1.10 (95% CI, 0.75–1.62) |
14/58 |
45/58 |
31/58 |
Br J Cancer |
15942629 |
|
5-FU plus leucovorin plus irinotecan |
FI2 |
56 |
61 |
40/16 |
46/10 |
10/46 |
29/27 |
4/49/3 |
37/19 |
24/56 |
15/56 |
29/56 |
|
Thuss-Patience 2005 |
Germany |
NA |
II |
NA |
5-FU plus docetaxel |
FT2 |
45 |
62 |
29/16 |
Western |
44/1 |
26/19 |
15/30 |
NA |
Measurable |
14/28/2 |
31/14 |
14/12 |
1.02 (95% CI, 0.68–1.54) |
0.96 (95% CI, 0.63–1.48) |
17/45 |
24/45 |
23/45 |
J Clin Oncol |
15659494 |
|
5-FU plus cisplatin plus epirubicin |
FP3 |
45 |
63 |
36/9 |
44/1 |
20/25 |
20/25 |
16/28/1 |
33/12 |
12/19 |
16/45 |
32/45 |
21/45 |
|
Pozzo 2004 |
Italy |
NA |
II |
January 1999—April 2000 |
5-FU plus leucovorin plus irinotecan |
FI2 |
74 |
57 |
57/17 |
Western |
68/6 |
33/41 |
13/61 |
28/46 |
57/17 |
11/63/0 |
61/12 |
22/34 |
0.56 (95% CI, 0.39–0.81) |
0.41 (95% CI, 0.26–0.64) |
25/74 |
33/74 |
36/74 |
Ann Oncol |
15550582 |
|
Cisplatin plus irinotecan |
PI2 |
72 |
59 |
46/26 |
69/3 |
39/33 |
16/56 |
30/42 |
57/15 |
7/65/0 |
49/23 |
27/29 |
18/72 |
68/72 |
33/72 |
|
Bouché 2004 |
France |
NA |
II |
January 1999—October 2001 |
5-FU plus leucovorin plus irinotecan |
FI2 |
45 |
65 |
38/7 |
Western |
Metastatic |
41/4 |
9/36 |
23/22 |
Measurable |
35/10 |
31/14 |
Balanced |
1 versus 2: 0.93 (95% CI, 0.54–1.58) |
1 versus 2: 0.84 (95% CI, 0.52–1.35) |
18/45 |
25/45-2 |
24/45 |
J Clin Oncol |
15514373 |
|
5-FU plus cisplatin plus leucovorin |
FP2 |
44 |
64 |
35/9 |
42/2 |
6/44 |
22/22 |
33/11 |
31/13 |
1 versus 3: 0.64 (95% CI, 0.38–1.08) |
1 versus 3: 0.47 (95% CI, 0.29–0.78) |
18/45 |
25/45-2 |
24/45 |
|
|
5-FU plus leucovorin |
F1 |
45 |
64 |
37/8 |
43/2 |
10/45 |
23/22 |
33/12 |
32/13 |
2 versus 3: 0.65 (95% CI, 0.39-1.10) |
2 versus 3: 0.59 (95% CI, 0.36–0.97) |
12/44 |
40/44-2 |
16/44 |
|
|
Koizumi 2004 |
Japan |
NA |
II |
July 1991—December 1996 |
Doxifluridine plus cisplatin plus mitomycin-C |
FP3 |
32 |
58 |
17/15 |
Eastern |
Metastatic and locally unresectable |
10/22 |
8/24 |
3/29 |
Measurable |
5/20/6 |
Gastric |
Balanced |
0.78 (95% CI, 0.43–1.41) |
NA |
8/32 |
14/32 |
7/32 |
Anticancer Res |
15330199 |
|
Doxifluridine plus cisplatin |
FP2 |
29 |
58 |
19/10 |
11/18 |
6/23 |
2/27 |
3/13/9 |
5/29 |
6/29 |
8/29 |
|
Cocconi 2003 |
Italy |
NA |
NA |
May 1993—November 1999 |
5-FU plus cisplatin plus leucovorin plus epirubicin |
FP3 |
98 |
62 |
67/31 |
Western |
82/16 |
NA |
NA |
49/49 |
Measurable |
0–2 |
Gastric |
NA |
0.90 (95% CI, 0.77–1.05) |
Median PFS time |
38/98 |
62/94 |
50/94 |
Ann Oncol |
12881389 |
|
5-FU plus doxorubicin plus methotrexate |
FA3 |
97 |
62 |
66/31 |
83/14 |
50/47 |
21/97 |
60/93 |
30/93 |
|
Ohtsu 2003 |
Japan |
NA |
III |
September 1992—March 1997 |
UFT plus mitomycin-C |
FY2 |
70 |
60.5 |
55/15 |
Eastern |
61/9 |
31/39 |
20/50 |
21/49 |
Measurable |
63/7 |
Gastric |
29/39 |
1 versus 2: 1.53 (95% CI, 1.11–2.11) |
1 versus 2: 2.16 (95% CI, 1.47–3.17) |
6/70 |
45/67-2 |
25/67 |
J Clin Oncol |
12506170 |
|
5-FU plus cisplatin |
FP2 |
105 |
63 |
77/28 |
90/15 |
55/50 |
28/77 |
29/76 |
95/10 |
49/52 |
1 versus 3: 1.29 (95% CI, 0.93–1.79) |
1 versus 3: 1.19 (95% CI, 0.84–1.69) |
36/105 |
81/102-2 |
40/102 |
|
5-FU |
F1 |
105 |
63 |
75/29 |
90/15 |
49/56 |
23/82 |
27/78 |
95/10 |
47/56 |
2 versus 3: 0.84 (95% CI, 0.63–1.11) |
2 versus 3: 0.63 (95% CI, 0.46–0.86) |
12/105 |
15/104-2 |
26/104 |
|
Tebbutt 2002 |
UK |
NA |
III |
July 1994—February 2001 |
5-FU |
F1 |
123 |
72* |
94/29 |
Western |
71/29 |
NA |
NA |
NA |
NA |
11/72/37 |
55/33/29*-E |
Balanced |
0.96 (95% CI, 0.75–1.22) |
1.09 (95% CI, 0.86–1.38) |
19/118 |
17/123 |
59/123 |
Ann Oncol |
12377644 |
|
5-FU plus mitomycin-C |
FY2 |
127 |
72* |
95/32 |
73/30 |
9/70/44 |
69/30/27*-E |
23/121 |
27/127 |
56/127 |
|
Kim 2001 |
South Korea |
NA |
III |
March 1997—April 2000 |
5-FU plus cisplatin plus epirubicin |
FP3 |
61 |
55 |
45/15 |
Eastern |
57/3 |
32/29 |
NA |
NA |
Measurable |
55/6 |
Gastric |
NA |
0.83 (95% CI, 0.42–1.61) |
Median PFS time |
22/61 |
23/61-2 |
32/61-3 |
Eur J Cancer |
10.1016/S0959-8049(01)81651-8 |
Abstract |
5-FU plus cisplatin |
FP2 |
60 |
56.5 |
42/18 |
57/3 |
28/32 |
53/7 |
20/60 |
10/60-2 |
10/60-3 |
Vanhoefer 2000 |
Germany |
NA |
III |
July 1991—April 1995 |
5-FU plus leucovorin plus etoposide |
FE2 |
132 |
59 |
90/38 |
Western |
110/22 |
NA |
NA |
78/54 |
122/10 |
54/66/12 |
Gastric |
57/45 |
1 versus 3: 0.95 (95% CI, 0.74–1.24) |
1 versus 3: 1.02 (95% CI, 0.79–1.32) |
7/79 |
68/129 |
62/129 |
J Clin Oncol |
10894863 |
|
5-FU plus cisplatin |
FP2 |
134 |
57 |
91/41 |
113/21 |
73/61 |
125/9 |
43/71/20 |
65/43 |
2 versus 3: 0.98 (95% CI, 0.86–1.12) |
2 versus 3: 0.94 (95% CI, 0.83–1.07) |
16/81 |
73/127 |
84/127 |
|
5-FU plus doxorubicin plus methotrexate |
FA3 |
133 |
58 |
96/34 |
111/22 |
67/66 |
122/11 |
36/81/16 |
59/47 |
|
|
10/85 |
89/122 |
57/122 |
|
Roth 1999 |
Croatia |
NA |
NA |
NA |
5-FU plus cisplatin plus epirubicin |
FP3 |
54 |
55 |
NA |
Western |
74/36 |
NA |
NA |
NA |
Measurable |
57/53 |
Gastric |
NA |
0.74 (95% CI, 0.55–0.99) |
NA |
16/56 |
Description |
Description |
Tumori |
10587023 |
|
5-FU plus epirubicin |
FA2 |
56 |
23/54 |
|
Waters 1999 |
UK |
NA |
NA |
July 1992—June 1995 |
5-FU plus doxorubicin plus methotrexate |
FA3 |
130 |
60 |
110/20 |
Western |
79/51 |
NA |
NA |
48/82 |
NA |
97/32 |
73/33/24*-E |
Balanced |
1.52 (95% CI, 1.19–1.95) |
1.79 (95% CI, 1.40–2.29) |
24/116 |
126/130-2 |
111/130 |
Br J Cancer |
10390007 |
|
5-FU plus cisplatin plus epirubicin |
FP3 |
126 |
59 |
99/27 |
79/47 |
51/75 |
96/30 |
72/27/27*-E |
56/121 |
60/126-2 |
122/126 |
|
Içli 1998 |
Turkey |
NA |
III |
1994–1997 |
5-FU plus cisplatin plus epirubicin |
FP3 |
67 |
52.7 |
40/27 |
Western |
53/14 |
NA |
NA |
NA |
Measurable |
8/38/21 |
Gastric |
NA |
1.23 (95% CI, 0.76–1.98) |
1.07 (95% CI, 0.58–1.96) |
9/59 |
4/67 |
15/67 |
Cancer |
9874451 |
|
Cisplatin plus epirubicin plus etoposide |
PA3 |
64 |
52.7 |
44/20 |
53/11 |
6/36/22 |
12/59 |
6/64 |
10/64 |
|
Yamamura 1998 |
Japan |
NA |
NA |
NA |
5-FU plus pirarubicin plus methotrexate |
FA3 |
37 |
NA |
NA |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
NA |
Gastric |
NA |
0.88 (95% CI, 0.55–1.41) |
NA |
NA |
Description |
Description |
Gan To Kagaku Ryoho |
9725047 |
Japanese |
5-FU |
F1 |
34 |
Barone 1998 |
Italy |
NA |
II |
January 1993—December 1995 |
Cisplatin plus epirubicin plus etoposide |
PA3 |
36 |
57.3 |
26/10 |
Western |
Metastatic and locally unresectable |
19/17 |
17/19 |
22/14 |
Measurable |
28/8 |
Gastric |
NA |
0.89 (95% CI, 0.55–1.42) |
Median PFS time |
6/33 |
Cycles |
Cycles |
Cancer |
9554521 |
|
5-FU plus leucovorin |
F1 |
36 |
59 |
24/12 |
17/19 |
18/18 |
20/16 |
28/8 |
7/32 |
|
Scheithauer 1996 |
Austria |
NA |
NA |
NA |
5-FU plus leucovorin plus doxorubicin |
FA2 |
52 |
NA |
NA |
Western |
65/38 |
NA |
NA |
NA |
NA |
73/30 |
Gastric |
NA |
0.49 (95% CI, 0.33–0.74) |
0.31 (95% CI, 0.21–0.45) |
NA |
NA |
NA |
Ann Hematol |
28850174 |
Abstract |
Supportive care |
S |
51 |
Colucci 1995 |
Italy |
NA |
NA |
NA |
5-FU plus leucovorin plus etoposide |
FE2 |
31 |
56 |
20/11 |
Western |
Metastatic and locally unresectable |
14/17 |
1/30 |
18/13 |
Measurable |
0–2 |
Gastric |
NA |
0.70 (95% CI, 0.42–1.16) |
NA |
13/31 |
4/31 |
15/31 |
Am J Clin Oncol |
8526196 |
|
5-FU plus leucovorin |
F1 |
31 |
58 |
20/11 |
17/14 |
1/30 |
20/11 |
9/31 |
2/31 |
4/31 |
|
Pyrhönen 1995 |
Finland |
NA |
III |
July 1986—June 1992 |
5-FU plus leucovorin plus epirubicin |
FA2 |
21 |
58 |
15/6 |
Western |
15/6 |
8/13 |
4/17 |
15/6 |
Measurable |
4/15/2 |
Gastric |
NA |
0.35 (95% CI, 0.15–0.81) |
0.29 (95% CI, 0.13–0.65) |
6/21 |
12/21 |
13/21 |
Br J Cancer |
7533517 |
|
Supportive care |
S |
20 |
58 |
10/10 |
14/6 |
8/12 |
2/18 |
16/4 |
3/15/2 |
0/20 |
0/20 |
0/20 |
|
Coombes 1994 |
UK |
NA |
NA |
August 1985—September 1988 |
Epirubicin |
A1 |
36 |
59.9 |
27/9 |
Western |
34/2 |
18/18 |
8/28 |
NA |
Measurable |
0–2 |
Gastric |
NA |
1.09 (95% CI, 0.56–2.12) |
NA |
3/36 |
3/36 |
25/36 |
Ann Oncol |
8172789 |
|
5-FU |
F1 |
33 |
55.6 |
24/9 |
31/2 |
15/18 |
5/28 |
2/33 |
4/33 |
9/33 |
|
Cocconi 1994 |
Italy |
NA |
III |
August 1988—November 1991 |
5-FU plus cisplatin plus leucovorin plus epirubicin |
FP3 |
85 |
62 |
60/25 |
Western |
78/7 |
NA |
NA |
31/21 |
46/6 |
0–3 |
Gastric |
NA |
0.69 (95% CI, 0.51–0.93) |
Median PFS time |
37/85 |
13/85 |
28/85 |
J Clin Oncol |
7989945 |
|
5-FU plus doxorubicin plus mitomycin-C |
FA3 |
52 |
65 |
42/10 |
43/9 |
54/31 |
76/9 |
8/52 |
1/52 |
8/52 |
|
Loehrer 1994 |
USA |
NA |
NA |
January 1985—January 1987 |
5-FU |
F1 |
69 |
59 |
NA |
Western |
44/25 |
34/35 |
16/53 |
NA |
47/22 |
12/34/22 |
Gastric |
NA |
1 versus 2: 0.75 (95% CI, 0.43–1.31) |
1 versus 2: 0.42 (95% CI, 0.21–0.83) |
5/40 |
21/69 |
48/69 |
Invest New Drugs |
7960608 |
|
Epirubicin |
A1 |
26 |
57 |
15/11 |
11/15 |
5/21 |
17/9 |
7/11/5 |
1 versus 3: 0.98 (95% CI, 0.67–1.44) |
1 versus 3: 1.02 (95% CI, 0.69–1.53) |
1/16 |
6/26 |
18/26 |
|
5-FU plus epirubicin |
FA2 |
70 |
62 |
45/25 |
35/35 |
16/54 |
50/20 |
16/31/14 |
2 versus 3: 1.25 (95% CI, 0.73–2.14) |
2 versus 3: 4.55 (95% CI, 2.40–8.65) |
4/33 |
48/70 |
68/70 |
|
Cullinan 1994 |
USA |
NA |
NA |
February 1984—March 1992 |
5-FU plus doxorubicin plus Me-CCNU plus triazinate |
FA4 |
79 |
60 |
53/26 |
Western |
Metastatic and locally unresectable |
NA |
NA |
31/48 |
16/63 |
55/24 |
Gastric |
Balanced |
1 versus 4: 0.95 (95% CI, 0.65–1.38) |
1 versus 4: 0.65 (95% CI, 0.46–0.94) |
NA |
47/79 |
47/79 |
J Clin Oncol |
8113849 |
|
5-FU plus cisplatin plus doxorubicin |
FP3 |
51 |
61 |
40/11 |
21/30 |
6/45 |
35/16 |
2 versus 4: 1.17 (95% CI, 0.77–1.76) |
2 versus 4: 0.84 (95% CI, 0.57–1.26) |
29/51 |
30/51 |
|
5-FU plus doxorubicin plus Me-CCNU |
FA3 |
53 |
63 |
43/10 |
18/35 |
6/47 |
36/17 |
3 versus 4: 0.97 (95% CI, 0.62–1.52) |
3 versus 4: 0.90 (95% CI, 0.60–1.34) |
34/53 |
16/53 |
|
5-FU |
F1 |
69 |
63 |
52/17 |
24/45 |
14/55 |
50/19 |
|
|
28/69 |
12/69 |
|
Murad 1993 |
Brazil |
NA |
II |
1988–1991 |
5-FU plus doxorubicin plus methotrexate |
FA3 |
30 |
58 |
20/10 |
Versatile |
21/9 |
NA |
NA |
13/17 |
Measurable |
5/16/9 |
Gastric |
NA |
0.33 (95% CI, 0.17–0.64) |
NA |
15/30 |
2/30 |
7/30 |
Cancer |
8508427 |
|
Supportive care |
S |
10 |
57 |
7/3 |
6/4 |
3/7 |
3/4/3 |
0/10 |
0/10 |
0/10 |
|
Kim 1993 |
South Korea |
NA |
III |
August 1986—June 1990 |
5-FU plus doxorubicin plus mitomycin-C |
FA3 |
98 |
54 |
68/30 |
Eastern |
Metastatic and locally unresectable |
34/64 |
NA |
22/76 |
57/41 |
75/23 |
Gastric |
22/48 |
1 versus 2: 1.36 (95% CI, 0.99–1.86) |
Median PFS time |
14/57 |
Cycles |
93/98-2 |
Cancer |
8508349 |
|
5-FU plus cisplatin |
FP2 |
103 |
51 |
71/32 |
38/65 |
15/88 |
55/48 |
83/20 |
30/52 |
1 versus 3: 1.21 (95% CI, 0.88–1.67) |
28/55 |
101/103-2 |
|
5-FU |
F1 |
94 |
54 |
66/28 |
33/61 |
10/84 |
54/50 |
76/18 |
26/45 |
2 versus 3: 0.84 (95% CI, 0.61–1.17) |
14/54 |
44/94-2 |
|
KRGGC 1992 |
South Korea |
NA |
NA |
NA |
5-FU plus cisplatin plus epirubicin |
FP3 |
25 |
NA |
NA |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
NA |
Gastric |
NA |
0.57 (95% CI, 0.27–1.20) |
NA |
5/21 |
Description |
Description |
Anticancer Res |
1295444 |
|
5-FU plus cisplatin |
FP2 |
22 |
6/22 |
|
Kelsen 1992 |
USA |
NA |
NA |
June 1988—October 1990 |
5-FU plus leucovorin plus doxorubicin plus methotrexate |
FA3 |
30 |
56 |
22/8 |
Western |
19/11 |
16/14 |
2/28 |
NA |
Measurable |
0–2 |
Gastric and junction |
NA |
0.79 (95% CI, 0.42–1.46) |
NA |
10/30 |
Description |
Description |
J Clin Oncol |
1548519 |
|
Cisplatin plus doxorubicin plus etoposide |
PA3 |
30 |
57 |
24/6 |
21/9 |
16/14 |
3/27 |
6/30 |
|
Kikuchi 1990 |
Japan |
NA |
NA |
NA |
5-FU plus cisplatin plus doxorubicin |
FP3 |
32 |
NA |
NA |
Eastern |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
NA |
Gastric |
NA |
0.58 (95% CI, 0.36–0.95) |
NA |
6/18 |
Description |
Description |
Gan To Kagaku Ryoho |
2181941 |
Japanese |
5-FU plus doxorubicin |
FA2 |
33 |
0/19 |
GITSG 1988 |
USA |
NA |
III |
November 1981—July 1985 |
5-FU plus cisplatin plus doxorubicin |
FP3 |
85 |
18–75 |
63/22 |
Western |
Metastatic |
41/44 |
NA |
NA |
31/54 |
58/27 |
Gastric |
NA |
1 versus 2: 0.98 (95% CI, 0.67–1.45) |
NA |
6/30 |
64/85 |
33/85 |
J Natl Cancer Inst |
2900901 |
|
5-FU plus doxorubicin plus triazinate |
FA3 |
81 |
60/21 |
32/49 |
30/51 |
53/28 |
1 versus 3: 0.71 (95% CI, 0.49–1.02) |
6/31 |
23/81 |
25/81 |
|
5-FU plus doxorubicin plus Me-CCNU |
FA3 |
81 |
51/30 |
40/41 |
33/48 |
51/30 |
2 versus 3: 0.71 (95% CI, 0.49–1.03) |
5/33 |
61/81 |
12/81 |
|
Lacave 1987 |
Spain |
NA |
III |
April 1979—June 1983 |
5-FU plus doxorubicin plus Me-CCNU |
FA3 |
85 |
58 |
55/30 |
Western |
65/20 |
32/53 |
43/42 |
60/25 |
28/57 |
0–3 |
Gastric |
NA |
0.82 (95% CI, 0.59–1.14) |
NA |
5/28 |
Description |
Description |
J Clin Oncol |
3305795 |
|
5-FU plus doxorubicin |
FA2 |
88 |
59 |
65/23 |
74/14 |
50/38 |
48/40 |
63/25 |
29/59 |
3/29 |
|
Levi 1986 |
Australia |
NA |
NA |
NA |
5-FU plus doxorubicin plus BCNU |
FA3 |
94 |
61 |
68/26 |
Western |
Metastatic and locally unresectable |
28/66 |
22/72 |
42/52 |
75/19 |
68/18 |
Gastric |
Balanced |
0.58 (95% CI, 0.43–0.77) |
0.62 (95% CI, 0.30–1.28) |
30/75 |
13/94 |
10/94 |
J Clin Oncol |
3528404 |
|
Doxorubicin |
A1 |
93 |
59 |
68/25 |
26/67 |
17/76 |
41/52 |
70/24 |
63/23 |
9/70 |
5/93 |
14/93 |
|
De Lisi 1986 |
Italy |
NA |
III |
NA |
5-FU plus doxorubicin plus mitomycin-C plus BCNU |
FA4 |
42 |
64 |
NA |
Western |
Metastatic and locally unresectable |
NA |
NA |
NA |
NA |
NA |
Gastric |
NA |
1.16 (95% CI, 0.26–5.15) |
NA |
9/41 |
Description |
Description |
Cancer Treat Rep |
3516397 |
|
5-FU |
F1 |
42 |
6/41 |
|
Cullinan 1985 |
USA |
NA |
NA |
NA |
5-FU |
F1 |
51 |
18–75 |
36/15 |
Western |
32/19 |
NA |
NA |
NA |
11/40 |
37/14 |
Gastric |
NA |
1 versus 2: 0.96 (95% CI, 0.60–1.52) |
1 versus 2: 0.99 (95% CI, 0.62–1.59) |
2/11 |
Description |
Description |
JAMA |
2579257 |
|
5-FU plus doxorubicin |
FA2 |
49 |
37/12 |
31/18 |
10/39 |
33/16 |
1 versus 3: 0.91 (95% CI, 0.56–1.48) |
1 versus 3: 1.17 (95% CI, 0.70–1.96) |
3/11 |
|
5-FU plus doxorubicin plus mitomycin-C |
FA3 |
51 |
39/12 |
31/20 |
13/38 |
32/19 |
2 versus 3: 0.99 (95% CI, 0.64–1.53) |
2 versus 3: 1.30 (95% CI, 0.82–2.06) |
5/13 |
|
Douglass 1984 |
USA |
NA |
NA |
NA |
5-FU plus doxorubicin plus Me-CCNU |
FA3 |
39 |
62 |
31/8 |
Western |
Metastatic and locally unresectable |
NA |
NA |
NA |
Measurable |
9/21/6 |
Gastric |
Balanced |
1 versus 2: 1.61 (95% CI, 0.88–2.92) |
NA |
11/39 |
14/39 |
3/39 |
J Clin Oncol |
6439836 |
|
5–FU plus doxorubicin plus mitomycin–C |
FA3 |
46 |
61 |
35/11 |
11/19/13 |
1 versus 3: 0.72 (95% CI, 0.39–1.35) |
18/46 |
14/46 |
1/46 |
|
5-FU plus Me-CCNU |
FU2 |
44 |
58 |
35/9 |
9/23/10 |
1 versus 4: 0.94 (95% CI, 0.54–1.64) |
6/44 |
13/44 |
4/44 |
|
Doxorubicin plus mitomycin-C |
AY2 |
46 |
59.5 |
33/13 |
8/20/14 |
13/46 |
13/46 |
6/46 |
|
|
O’Connel 1984 |
USA |
NA |
NA |
December 1978—March 1981 |
5-FU plus doxorubicin plus Me-CCNU |
FA3 |
76 |
62 |
53/23 |
Western |
60/16 |
29/41 |
NA |
NA |
16/44 |
18/38/20 |
Gastric |
Balanced |
1 versus 2: 0.89 (95% CI, 0.58–1.37) |
NA |
4/16 |
60/76 |
11/76 |
Cancer |
6418371 |
|
5-FU plus doxorubicin plus mitomycin-C |
FA3 |
78 |
62 |
52/26 |
62/16 |
23/46 |
18/44 |
17/38/23 |
1 versus 3: 0.82 (95% CI, 0.54–1.26) |
3/18 |
40/78 |
7/78 |
|
5-FU plus doxorubicin |
FA2 |
78 |
60 |
57/21 |
60/18 |
21/54 |
19/41 |
16/40/22 |
2 versus 3: 0.92 (95% CI, 0.62–1.39) |
1/19 |
32/78 |
7/78 |
|
Friedman 1983 |
USA |
NA |
III |
December 1977– December 1980 |
Tegafur plus doxorubicin plus BCNU |
FA3 |
36 |
18–75 |
24/12 |
Western |
27/9 |
NA |
NA |
15/21 |
22/14 |
0–3 |
Gastric |
NA |
1.03 (95% CI, 0.64–1.66) |
NA |
3/22 |
9/36 |
4/36 |
Cancer |
6414682 |
|
5-FU plus doxorubicin |
FA2 |
38 |
22/16 |
28/10 |
19/19 |
19/19 |
1/19 |
14/38 |
2/38 |
|
Tegafur plus doxorubicin plus mitomycin-C |
FA3 |
34 |
22/12 |
Eastern |
28/6 |
8/29 |
12/22 |
0.79 (95% CI, 0.39–1.59) |
NA |
1/12 |
10/34 |
0/34 |
|
5-FU plus doxorubicin |
FA2 |
34 |
21/13 |
27/7 |
5/26 |
22/12 |
3/22 |
5/34 |
1/34 |
|
O’Connel 1982 |
USA |
NA |
NA |
NA |
5-FU plus doxorubicin plus mitomycin-C |
FA3 |
43 |
62 |
29/14 |
Western |
Metastatic and locally unresectable |
NA |
NA |
NA |
12/31 |
18/25 |
Gastric |
NA |
1 versus 2: 1.13 (95% CI, 0.57–2.25) |
Median PFS time |
3/12 |
7/43 |
Description |
Cancer |
7037163 |
|
5-FU plus doxorubicin plus Me-CCNU |
FA3 |
34 |
59 |
25/9 |
10/24 |
21/13 |
1 versus 3: 0.69 (95% CI, 0.38–1.26) |
3/10 |
7/34 |
|
|
5-FU plus Me-CCNU plus razoxane |
FU3 |
46 |
62 |
32/14 |
19/27 |
17/29 |
1 versus 4: 0.87 (95% CI, 0.46–1.64) |
4/19 |
15/46 |
|
|
5-FU plus Me-CCNU |
FU2 |
58 |
64 |
34/24 |
18/40 |
29/29 |
|
1/18 |
17/58 |
|
|
Buroker 1979 |
USA |
NA |
II |
March 1975– March 1977 |
5-FU plus mitomycin-C |
FY2 |
80 |
18–75 |
NA |
Western |
Metastatic and locally unresectable |
28/52 |
NA |
NA |
43/37 |
NA |
Gastric |
NA |
0.86 (95% CI, 0.60–1.21) |
NA |
6/43 |
Cycles |
Cycles |
Cancer |
387204 |
|
5-FU plus Me-CCNU |
FU2 |
88 |
40/48 |
55/33 |
5/54 |
|